Clinical pharmacokinetics of oral contraceptive steroids

MLE Orme, DJ Back, AM Breckenridge - Clinical pharmacokinetics, 1983 - Springer
Oral contraceptive steroids are of 2 types: oestrogens, of which ethinyloestradiol is the most
important, and progestagens, of which levonorgestrel and norethisterone are the most …

Absorption from the vagina

DP Benziger, J Edelson - Drug metabolism reviews, 1983 - Taylor & Francis
Although this of the Journal of the American Medical Association replied," There is no
absorption from the intact vaginal mucosa." statement was quickly challenged [21, as late as …

Tissue concentrations of levonorgestrel in women using a levonorgestrel‐releasing IUD

CG Nilsson, M Haukkamaa, H Vierola… - Clinical …, 1982 - Wiley Online Library
Thirteen women who were scheduled for hysterectomy volunteered for the study. Nine
women had a levonorgestrel‐releasing intrauterine contraceptive device inserted between …

Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA

A Ortiz, M Hiroi, FZ Stanczyk… - The Journal of …, 1977 - academic.oup.com
A sensitive radioimmunoassay measuring serum medroxyprogesterone acetate (MPA) has
been developed in order to measure and correlate serum MPA concentrations and ovarian …

Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device

CG Nilsson, PLA Lähteenmäki, T Luukkainen - Fertility and sterility, 1984 - Elsevier
The ovarian function of 20 healthy users of a levonorgestrel-releasing intrauterine device
was studied by measurements of plasma estradiol, progesterone, and levonorgestrel …

Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity

AB Edelman, NE Carlson, G Cherala, MY Munar… - Contraception, 2009 - Elsevier
BACKGROUND: This study was conducted to determine whether increased body mass
index (BMI) affects oral contraceptive (OC) pharmacokinetics and suppression of …

Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women

CL Westhoff, AH Torgal, ER Mayeda, MC Pike… - Contraception, 2010 - Elsevier
BACKGROUND: This study was conducted to compare oral contraceptive (OC)
pharmacokinetics (PK) in normal-weight [body mass index (BMI) 19.0–24.9] and obese (BMI …

The impact of the menstrual cycle and hormonal contraceptives on competitiveness

T Buser - Journal of Economic Behavior & Organization, 2012 - Elsevier
We examine whether competitiveness in women is influenced by biological factors. Female
participants in a laboratory experiment solve a simple arithmetics task first under a piece rate …

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal …

AR Thurman, JL Schwartz, V Brache, MR Clark… - PloS one, 2018 - journals.plos.org
To prevent the global health burdens of human immunodeficiency virus [HIV] and
unintended/mistimed pregnancies, we developed an intravaginal ring [IVR] that delivers …

Five years' experience with levonorgestrel-releasing IUDs

T Luukkainen, H Allonen, M Haukkamaa… - Contraception, 1986 - Elsevier
Two levonorgestrel-releasing IUDs and a copper-releasing IUD of the same shape were
studied in a randomized comparative study over five years. The levonorgestrel-releasing …